Alembic Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 29 July 2019.

Powered by Capital Market - Live News

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 June 2019.

Powered by Capital Market - Live News

Alembic Pharmaceuticals announced that the Company has received approvalfrom the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application(ANDA) Carbidopa and Levodopa Extended-Release Tablets USP, 2.5 mg/100 mg and 50mg/200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug(RLD), Sinemet CR Tablets, 25 mg/100 mg and 50 mg/200 mg, of Merck Sharp & DohmeCorp. Carbidopa and Levodopa Extended-Release Tablets, USP are indicated in thetreatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomaticparkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Carbidopa and Levodopa Extended-Release Tablets USP, 25 mg/100 mg and 50 mg/200 mghave an estimated market size of US$ 24 million for twelve months ending December 2018according to IQVIA.

Carbidopa and Levodopa Extended-Release Tablets USP, 25 mg/100 mg and 50 mg/200 mghave an estimated market size of US$ 24 million for twelve months ending December 2018according to IQVIA.

Powered by Capital Market - Live News

Alembic Pharmaceuticals has received US Food & Drug Administration (USFDA) Approval for Solifenacin Succinate Tablets, 5 mg and 10 mg.

Theapproved ANDA is therapeutically equivalent to the reference listed drug (RLD),Vesicare Tablets, 5 mg and 10 mg, of Astellas Pharma US, Inc. Solifenacin SuccinateTablet is a muscarinic antagonist indicated for the treatment of overactive bladder withsymptoms of urge urinary incontinence, urgency, and urinary frequency.

Solifenacin Succinate Tablets, 5 mg and 10 mg have an estimated market size of US$967 million for twelve months ending December 2018 according to IQVIA.

Alembic now has a total of 94 ANDA approvals (82 final approvals and 12 tentativeapprovals) from USFDA.

Powered by Capital Market - Live News